Abstract
Background: We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH). Methods: Fifteen patients were included in this study. The drug (BTA; 150 IU) was reconstituted in 20 mL of 0.9% saline before administration to the patients. After providing urethral anesthesia, 20 intraurethral injections were made to lateral lobes of the prostate, 10 injections in each lobe. Follow-up visits were planned 3 and 12 months after the intervention. Pre- and post-interventional IPSS, Prostate-Specific Antigen (PSA), Prostate Volume (PV), Post-Void Residue (PVR), and maximum urinary flow rate (Qmax) compared via paired t-test. Finally, we reviewed the Pubmed database to provide a more precise conclusion. Results: The Mean±SD age of patients was 69±8.24 years, and the mean IPSS score decreased significantly from 24.3±3.3 to 14.6±3.7 (p<0.001) and 16.86±3.06 (p<0.009) on the 3rd and 12th months, respectively. The Mean±SD PSA, PVR, Qmax, and PV were 3.26±1.38, 82.33±35.55, 8.56±1.76, and 47.86±8.93, respectively at baseline. These factors significantly improved to 2.72±1.33 (P<0.000), 71.33±30.55 (p<0.000), 9.5±1.33 (p<0.011), and 42.86± 6.04 (p<0.000), respectively, on the 12th month follow-up. Conclusion: Although the overall results support the efficacy of BTA for BPH, the best route of administration, the most effective dose, the optimal number, and the volume of injections need further investigations. The probable placebo effect and underlying medical conditions (e.g., insulin resistance) should be considered as the confounding factors.
Highlights
B enign Prostatic Hypertrophy (BPH) is a common condition affecting at least 50% of men after age 50 [1]
Human studies have shown that hyperlipidemia alone does not increase the risk of Benign Prostatic Hyperplasia (BPH), unless one of the other components of metabolic syndrome is present [20]. These findings suggest that the studies which are conducted on the effects of Botox injection [6]. Intraprostatic onabotulinumtoxin-A (BTA) on BPH should consider the underlying endocrine status of patients as a confounding factor
We suggest that the effect of intraprostatic saline injections be explored on the BPH and/or the Lower Urinary Tract Symptoms (LUTS)
Summary
B enign Prostatic Hypertrophy (BPH) is a common condition affecting at least 50% of men after age 50 [1]. Since 15%-25% of patients who undergo TURP are not satisfied with the long-term clinical outcomes, younger patients prefer less invasive interventions to save their sexual and urinary functions from being endangered by unwanted complications of TURP [2, 5]. In such circumstances, the alternative options may be LASER prostatectomy, photoselective prostate vaporization, bipolar transurethral enucleation, prosthetic arterial embolization, and intraprostatic alcohol injection. A meta-analysis proposed a potent placebo effect, it is still worth attention because several studies have shown improvement in objective measures, such as Prostate Volume (PV), maximum urinary flow rate (Qmax), and Post-Void Residue (PVR). We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
